Adial Pharmaceuticals Inc expected to post a loss of $1.50 a share - Earnings Preview

Adial Pharmaceuticals

12/08/2023 03:04

* Adial Pharmaceuticals Inc  ADIL.OQ   ADIL.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 14 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Adial
Pharmaceuticals Inc
is for a loss of $1.50 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adial
Pharmaceuticals Inc is $150​, above​ its last closing price
of $4.40. ​​​

This summary was machine generated August 12 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated